glp 1 heart health Stopping GLP-1 drugs can quickly erase cardiovascular benefits – WashU Medicine Glucagon-like peptide 1 receptor agonists:

Description

Founders and investors see massive potential in the new drug class but funding is yet to flood startups in the sector.

A new study published in April sheds light on the concerns of anesthesiologists across the United States related to the perioperative management of patients taking glucagon-like peptide-1 (GLP-1) agonists, a class of drugs now commonly prescribed for both diabetes and cosmetic weight loss

Explore our recent survey findings showing physicians' growing concerns on GLP-1 overprescribing, long-term sustainability, and the future of obesity treatment.

Each generation has generated more research attention than the last, and the terminology has evolved alongside the chemis

Heart failure (HF) remains one of the cardiovascular diseases (CVDs) associated with a high unmet medical need due to high morbidity and mortality rates and ...